Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study

Sophie de Seigneux, Belen Ponte, Lucien Weiss, Jérôme Pugin, Jacques André Romand, Pierre-Yves Martin, Patrick Saudan, Sophie de Seigneux, Belen Ponte, Lucien Weiss, Jérôme Pugin, Jacques André Romand, Pierre-Yves Martin, Patrick Saudan

Abstract

Background: Experimentally, erythropoietin (EPO) has nephroprotective as well as immunomodulatory properties when administered after ischemic renal injury. We tested the hypothesis that different doses of recombinant human EPO administered to patients after cardiac surgery would minimize kidney lesions and the systemic inflammatory response, thereby decreasing acute kidney injury (AKI) incidence.

Methods: In this double-blinded randomized control study, 80 patients admitted to the ICU post-cardiac surgery were randomized by computer to receive intravenously isotonic saline (n = 40) versus α-Epoetin (n = 40): either 40000 IU (n = 20) or 20000 IU (n = 20). The study lasted one year. The primary outcome was the change in urinary NGAL concentration from baseline and 48 h after EPO injection. Creatinine, cystatine C and urinary NGAL levels were measured on the day of randomization and 2-4 days after EPO injection. To assess acute inflammatory response, serum cytokines (IL6 and IL8) were measured at randomization and four days after r-HuEPO injection. Patients and care-takers were blinded for the assignment.

Results: No patient was excluded after randomization. Patient groups did not differ in terms of age, gender, comorbidities and renal function at randomization. The rate of AKI assessed by AKIN criteria was 22.5% in our population. EPO treatment did not significantly modify the difference in uNGAl between 48 hours and randomization compared to placebo [2.5 ng/ml (-17.3; 22.5) vs 0.7 ng/ml (-31.77; 25.15), p = 0.77] and the incidence of AKI was similar. Inflammatory cytokines levels were not influenced by EPO treatment. Mortality and hospital stays were similar between the groups and no adverse event was recorded.

Conclusion: In this randomized-controlled trial, α-Epoetin administrated after cardiac surgery, although safe, demonstrated neither nephroprotective nor anti-inflammatory properties.

Trial registration number: NCT00676234.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Changes in renal biomarkers at randomization, 48 h (R-48 h) and 96 h (R-96 h) according to treatment group. Panels a, b and c represent creatinine, cystatine C and urinary NGAL differences, respectively (*outliers). NS: non significant.
Figure 3
Figure 3
Interleukin levels over time in presence or absence of AKI. Panel a and panel b represent IL6 and IL 8 at randomization and 96 hours, respectively, in patient with and without AKI (*outliers). p compares groups using log transformation.

References

    1. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141(1):14–31. doi: 10.1111/j.1365-2141.2008.07014.x.
    1. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif. 2010;29(2):86–92. doi: 10.1159/000245630.
    1. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006;69(10):1806–1813. doi: 10.1038/sj.ki.5000356.
    1. Uchino S, Kellum JA, Bellomo R. et al.Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–818. doi: 10.1001/jama.294.7.813.
    1. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19(2):348–355. doi: 10.1093/ndt/gfg547.
    1. Sharples EJ, Patel N, Brown P. et al.Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15(8):2115–2124. doi: 10.1097/01.ASN.0000135059.67385.5D.
    1. Yang CW, Li C, Jung JY. et al.Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17(12):1754–1755.
    1. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;1(1):3. doi: 10.1186/2110-5820-1-3.
    1. Mehta RL, Kellum JA, Shah SV. et al.Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi: 10.1186/cc5713.
    1. Ricci Z, Cruz D, Ronco C. The RIFLE classification for acute kidney injury definition. Am J Surg. 2009;198(1):152–153. doi: 10.1016/j.amjsurg.2008.06.033.
    1. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute kidney injury: a relevant complication after cardiac surgery. Ann Thorac Surg. 2011;92(4):1539–1547. doi: 10.1016/j.athoracsur.2011.04.123.
    1. Lassnigg A, Schmidlin D, Mouhieddine M. et al.Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004;15(6):1597–1605. doi: 10.1097/01.ASN.0000130340.93930.DD.
    1. Haase M, Bellomo R, Devarajan P. et al.Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009;88(1):124–130. doi: 10.1016/j.athoracsur.2009.04.023.
    1. Haase M, Devarajan P, Haase-Fielitz A. et al.The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57(17):1752–1761. doi: 10.1016/j.jacc.2010.11.051.
    1. Koyner JL, Vaidya VS, Bennett MR. et al.Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol. 2010;5(12):2154–2165. doi: 10.2215/CJN.00740110.
    1. Park M, Coca SG, Nigwekar SU, Garg AX, Garwood S, Parikh CR. Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Am J Nephrol. 2010;31(5):408–418. doi: 10.1159/000296277.
    1. Chawla LS, Seneff MG, Nelson DR. et al.Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol. 2007;2(1):22–30.
    1. Gueret G, Lion F, Guriec N. et al.Acute renal dysfunction after cardiac surgery with cardiopulmonary bypass is associated with plasmatic IL6 increase. Cytokine. 2009;45(2):92–98. doi: 10.1016/j.cyto.2008.11.001.
    1. Bian XX, Yuan XS, Qi CP. Effect of recombinant human erythropoietin on serum S100B protein and interleukin-6 levels after traumatic brain injury in the rat. Neurol Med Chir (Tokyo) 2010;50(5):361–366. doi: 10.2176/nmc.50.361.
    1. Shen Y, Wang Y, Li D. et al.Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplant Proc. 2010;42(5):1595–1597. doi: 10.1016/j.transproceed.2009.11.050.
    1. Licker M, Diaper J, Cartier V. et al.Clinical Review: Management of weaning from cardiopulmonary bypass after cardiac surgery. Ann Card Anaesth. 2012;15(3):206–223. doi: 10.4103/0971-9784.97977.
    1. Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand J Clin Lab Invest. 2010;70(5):374–382. doi: 10.3109/00365513.2010.486868.
    1. Song YR, Lee T, You SJ. et al.Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009;30(3):253–260. doi: 10.1159/000223229.
    1. Endre ZH, Walker RJ, Pickering JW. et al.Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial) Kidney Int. 2010;77(11):1020–1030. doi: 10.1038/ki.2010.25.
    1. Martinez F, Kamar N, Pallet N. et al.High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant. 2010;10(7):1695–1700. doi: 10.1111/j.1600-6143.2010.03142.x.
    1. Hall IE, Coca SG, Perazella MA. et al.Risk of Poor Outcomes with Novel and Traditional Biomarkers at Clinical AKI Diagnosis. Clin J Am Soc Nephrol. 2011;6(12):2740–2749. doi: 10.2215/CJN.04960511.
    1. Mishra J, Dent C, Tarabishi R. et al.Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231–1238. doi: 10.1016/S0140-6736(05)74811-X.
    1. Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant. 2008;23(6):1970–1974. doi: 10.1093/ndt/gfm908.
    1. Solling C, Christensen AT, Krag S. et al.Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand. 2011;55(2):185–195. doi: 10.1111/j.1399-6576.2010.02369.x.
    1. Liu KD, Altmann C, Smits G. et al.Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case–control study. Crit Care. 2009;13(4):R104. doi: 10.1186/cc7940.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe